IND223
NCT02905318
IND223
A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients With Metastatic Castration-Resistant Prostate Cancer
Status:
Recruiting
II
Phase
2nd+
Line of Therapy
Advanced / Metastatic
Disease Stage
Biomarker(s)
N/A
Investigational
Product
Palbociclib
CDK4/6 Inhibitor (p.o.)
Treatment Arms
o Experimental: Palbociclib